The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
Michael Wang, MD discusses progress in the field of treating mantle cell lymphoma, and the results of the SYMPATICO clinical trial which assessed the efficacy of ibrutinib combined with venetoclax among newly diagnosed patients.
Michael Wang, MD discusses progress in the field of treating mantle cell lymphoma, and the results of the SYMPATICO clinical trial which assessed the efficacy of ibrutinib combined with venetoclax among newly diagnosed patients.
At the 2025 Great Debates in Hematologic Malignancies meeting, Tycel Phillips, MD, debates the benefits of utilizing first-line BTK inhibitors to improve overall survival among certain patients with MCL.
At the 2025 Great Debates in Hematologic Malignancies meeting, Tycel Phillips, MD, debates the benefits of utilizing first-line BTK inhibitors to improve overall survival among certain patients with MCL.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
Tabelecleucel demonstrated durable responses and favorable safety among pediatric patients with relapsed/refractory Epstein–Barr virus-positive PTLD, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Tabelecleucel demonstrated durable responses and favorable safety among pediatric patients with relapsed/refractory Epstein–Barr virus-positive PTLD, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
